Answers are grounded in this paper and cite their sources.
We report the case of a 53-year-old man with immune thrombotic thrombocytopenic purpura (iTTP) who presented with microangiopathic hemolytic anemia and thrombocytopenia. The diagnosis was confirmed by undetectable ADAMTS13 activity and the presence of anti-ADAMTS13 autoantibodies. The initial episode coincided with the diagnosis of classical Hodgkin lymphoma with splenic involvement. Over 11 years, five acute episodes occurred, corresponding to three clinical relapses and one early exacerbation. Treatment included plasma exchange, corticosteroids, caplacizumab, and several courses of rituximab in a previously splenectomized patient. Given the high cumulative disease burden, a multidisciplinary discussion led to the initiation of subcutaneous rituximab maintenance at 1,400 mg every two months, with a planned total duration of two years. At the time of this report, the patient had completed approximately one year of maintenance therapy, and treatment was ongoing. During this period, no further clinical relapses were documented, and ADAMTS13 activity remained above 50% in the available assessments. Fixed rituximab maintenance may represent an individualized relapse-prevention strategy in selected patients with recurrent iTTP, although further evidence is required to establish its efficacy and safety.
No takes yet. Share an insight, caveat, or question.
Santos et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: